Which is currently the best strategy for treatment of SFA in-stent restenosis?

Journal of Cardiovascular Surgery

Volumn 55, Issue 4, 2014, Pages 477-481

  Elens, M ^a   Verbist, J ^a   Keirse, K ^b   Van Den Eynde, W ^a   Peeters, P ^a  

^a IMELDA HOSPITAL   (Belgium)

^b Regionaal Ziekenhuis Tienen   (Belgium)

Author keywords

Coronary restenosis; Femoral artery; Stents

Indexed keywords

PACLITAXEL; RAPAMYCIN; RHENIUM 188; BIOMATERIAL; CARDIOVASCULAR AGENT;

ARTERY PROSTHESIS; ARTICLE; ATHERECTOMY; ATHERECTOMY DEVICE; BRACHYTHERAPY; DRUG ELUTING STENT; FEMORAL ARTERY; HUMAN; IN-STENT RESTENOSIS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RADIATION SAFETY; STENT FRACTURE; SUPERFICIAL FEMORAL ARTERY; SUPERFICIAL FEMORAL ARTERY STENT; ADVERSE EFFECTS; CENTRAL VENOUS CATHETER; DEVICES; PATHOPHYSIOLOGY; PERIPHERAL ARTERIAL DISEASE; PROCEDURES; PROSTHESIS; PROSTHESIS FAILURE; RECURRENT DISEASE; RISK FACTOR; STENOSIS, OCCLUSION AND OBSTRUCTION; STENT; TIME; TREATMENT OUTCOME; VASCULAR PATENCY;

ANGIOPLASTY, BALLOON; ATHERECTOMY; CARDIOVASCULAR AGENTS; COATED MATERIALS, BIOCOMPATIBLE; CONSTRICTION, PATHOLOGIC; DRUG-ELUTING STENTS; FEMORAL ARTERY; HUMANS; PERIPHERAL ARTERIAL DISEASE; PROSTHESIS DESIGN; PROSTHESIS FAILURE; RECURRENCE; RISK FACTORS; STENTS; TIME FACTORS; TREATMENT OUTCOME; VASCULAR ACCESS DEVICES; VASCULAR PATENCY;

EID: 84908155936     PISSN: 00219509     EISSN: 1827191X     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Payne MM. Charles Theodore Dotter. The father of intervention. Tex Heart Inst J 2001;28:28-38.
2. Bosiers M, Deloose K, Callaert J, Maene L, Keirse K, Verbist J et al. Refining stent technologies for femoral interventions. J Cardiovasc Surg (Torino) 2012;53:465-73.
3. Soga Y, Iida O, Hirano K, Suzuki K, Yokoi H, Nobuyoshi M. Restenosis after stent implantation for superficial femoral artery disease in patients treated with cilostazol. Catheter Cardiovasc Interv 2012;79:541-8.
4. Ikushima I, Yonenaga K, Iwakiri H, Nagoshi H, Kumagai H, Yamashita Y. A better effect of cilostazol for reducing in-stent restenosis after femoropopliteal artery stent placement in comparison with ticlopidine. Med Devices (Auckl) 2011;4:83-9.
5. Hoffmann R, Mintz GS, Dussaillant GR, Popma JJ, Pichard AD, Satler LF et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation 1996;94:1247-54.
6. Scheinert D, Scheinert S, Sax J, Piorkowski C, Briiunlich S, Ul-rich M et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol 2005;45:312-5.
7. Bosiers M, Torsello G, Gissler HM, Ruef J, Miiller-Hulsbeck S, Jahnke T et al. Nitinol stent implantation in long superficial femoral artery lesions: 12-month results of the DURABILITY I study. J Endovasc Ther 2009;16:261-9.
8. Soga Y, Iida O, Hirano K, Suzuki K, Yokoi H, Nobuyoshi M. Restenosis after stent implantation for superficial femoral artery disease in patients treated with cilostazol. Catheter Cardiovasc Interv 2012;79:541-8.
9. Katzen B. The resilient trial 12-month analysis. Transcatheter cardiovascular therapeutics 2007. Washington Conference Center, Washington DC; Oct 23, 2007;
10. J Vase Interv Radiol 2005;16:331-8.
11. Matsumura JS, Yamanouchi D, Goldstein JA, Pollock CW, Bosiers M, Schultz GA et al. The United States StuDy for Evaluating EndovasculaR TreAtments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By using the Protege Everftex Nitinol STent System IKDURABILITY II). J Vase Surg 2013;58:73-83.el.
12. Duda SH, Bosiers M, Lammer J, Scheinert D, Zeller T, Tielbeek A et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vase Interv Radiol 2005;16:331-8.
13. Liistro F, Grotti S, Porto I, Angioli P, Ricci L, Ducci K et al. Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial (drug eluting balloon in peripheral intervention for the superficial femoral artery). JACC Cardiovasc Interv 2013;6:1295-302.
14. Dick P, Sabeti S, Mlekusch W, Schlager O, Amighi J, Haumer M et al. Conventional balloon angioplasty versus peripheral cutting balloon angioplasty for treatment of femoropopliteal artery in-stent restenosis: initial experience. Radiology 2008;248:297-302.
15. Tosaka A, Soga Y, Iida O, Ishihara T, Hirano K, Suzuki K et al. Classification and clinical impact of restenosis after femoropopliteal stenting. J Am Coll Cardiol 2012;59:16-23.
16. Zeller T, Rastan A, Sixt S, Schwarzwalder U, Schwarz T, Frank U et al. Long-term results after directional atherectomy of femoropopliteal lesions. J Am Coll Cardiol 2006;48:1573-8.
17. Trentmann J, Charalambous N, Djawanscher M, Schafer J, Jahnke T. Safety and efficacy of directional atherectomy for the treatment of in-stent restenosis of the femoropopliteal artery. J Cardiovasc Surg (Torino) 2010;51:551-60.
18. Brodmann M, Rief P, Froehlich H, Dorr A, Gary T, Eller P et al. Neointimal hyperplasia after silverhawk atherectomy versus percutaneous transluminal angioplasty (PTA) in femoropopliteal stent reobstructions: a controlled, randomized pilot trial. Cardiovasc Intervent Radiol 2013;36:69-74.
19. Schmidt A, Zeller T, Sievert H, Krankenberg H, Torsello G, Stark MA et al. Photoablation using the turbo-booster and exci-mer laser for in-stent restenosis treatment: twelve-month results from the PATENT study. J Endovasc Ther 2014;21:52-60.
20. Silingardi R, Cataldi V, Moratto R, Azzoni I, Veronesi J, Coppi G. Mechanical thrombectomy in in-stent restenosis: preliminary experience at the iliac and femoropopliteal arteries with the Rotarex System. J Cardiovasc Surg (Torino) 2010;51:543-50.
21. Wissgott C, Kamusella P, Andresen R. Treatment of in-stent re-occlusions of femoropopliteal arteries with mechanical rotational catheters]. Rofo 2011;183:939-44.
22. Shammas NW, Shammas GA, Jerin M. Differences in patient selection and outcomes between SilverHawk atherectomy and laser ablation in the treatment of femoropopliteal in-stent restenosis: a retrospective analysis from a single center. J Endovasc Ther 2013;20:844-52.
23. Saxon RR, Coffman JM, Gooding JM, Ponec DJ. Long-term patency and clinical outcome of the Viabahn stent-graft for femoropopliteal artery obstructions. J Vase Interv Radiol 2007;18:1341-9; quiz 1350.
24. Bosiers M, Deloose K, Keirse K, Verbist J, Peeters P. Prevention and treatment of in-stent restenosis. J Cardiovasc Surg (Torino) 2010;51:591-8.
25. Al Shammed O, Bitar F, Ghitelman J, Soukas PA. Viabahn for femoropopliteal in-stent restenosis. Ann Saudi Med 2012;32:572-82.
26. Gorgani F, Telis A, Narakathu N, Labarbera M, Babaev A. Long-term outcomes of the viabahn stent in the treatment of in-stent restenosis in the superficial femoral artery. J Invasive Cardiol 2013;25:670-4.
27. Miki K, Fujii K, Kawasaki D, Fukunaga M, Nishimura M, Hori-matsu T et al. effect of bare-metal nitinol stent implantation and paclitaxel-eluting nitinol stent implantation on vascular response in the superficial femoral artery lesion assessed on intravascular ultrasound. Circ J 2014 [Epub ahead of print].
28. Curcio A, Torella D, Indolfi C. Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: approach to therapy. Circ J 2011;75:1287-96.
29. Axel DI, Kunert W, Goggelmann C, Oberhoff M, Herdeg C, Kiit-tner A, Wild DH et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997;96:636-45.
30. Leopardi M, Houbballah R, Becquemin JP. Effectiveness of Zil-ver PTX eluting stent in TASC C/D lesions and restenosis. J Cardiovasc Surg (Torino) 2014;55:229-34.
31. Zeller T, Dake MD, Tepe G, Brechtel K, Noory E, Beschomer U et al. Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents. JACC Cardiovasc Interv 2013;6:274-81.
32. Stabile E, Virga V, Salemme L, Cioppa A, Ambrosini V, Sor-ropago G et al. Drug-eluting balloon for treat- ment of superficial femoral artery in-stent restenosis. J Am Coll Cardiol 2012;60:1739-42.
33. Virga V, Stabile E, Biamino G, Salemme L, Cioppa A, Giugliano G et al. Drug-eluting balloons for the treatment of the superficial femoral artery in-stent restenosis: 2-year follow-up. JACC Cardiovasc Interv 2014;7:411-5.
34. Sixt S, Carpio Cancino OG, Treszl A, Beschorner U, Machar-zina R, Rastan A et al. Drug-coated balloon angioplasty after directional atherectomy improves outcome in restenotic femoropopliteal arteries. J Vase Surg 2013;58:682-6.
35. Gandini R, Del Giudice C, Merolla S, Morosetti D, Pampana E, Si-monetti G. Treatment of chronic SEA in-stent occlusion with combined laser atherectomy and drug-eluting balloon angioplasty in patients with critical limb ischemia: a single-center, prospective, randomized study. J Endovasc Ther 2013;20:805-14.
36. Werner M, Scheinert D, Henn M, Scheinert S, Braunlich S, Bausback Y et al. Endovascular brachytherapy using liquid Beta-emitting rhenium-188 for the treatment of long-segment femoropopliteal in-stent stenosis. J Endovasc Ther 2012;19:467-75.